DIMERIX QUARTERLY ACTIVITIES REPORT
Quarter highlights
• Last patient completed dosing in FSGS Phase 2 clinical study in June 2020, with data
expected by end July 2020
• DMX-200 selected for inclusion in the WHO endorsed REMAP-CAP global study protocol
for Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19
• $5.8 million placement to Institutions as well as new and existing sophisticated investors
completed in June 2020
• Dimerix received $1.02 million in prepayment of R&D tax incentive claim in April 2020
• Cash position of $7.8 million at 30 June 2020 ($2.47 million at 31 March 2020)
MELBOURNE, Australia, 14 July 2020: Dimerix Limited (ASX: DXB) (“Dimerix” or the “Company”),
a clinical-stage biopharmaceutical company, today announced its Appendix 4C and Quarterly
Activities Report for the period ended 30 June 2020. Despite COVID-19 global pandemic, the
Company has gained material traction and momentum across all of its target activities through
the quarter, executing in line with the strategic plan. The Company continues to consistently
demonstrate its ability to plan, develop, execute and deliver on its strategic goals.
Dimerix ended the quarter with cash of $7.8 million ($2.47 million at 31 March 2020), with net
operating cash outflows for the period of $1.2 million ($1.39 million in the prior quarter) and total
net operating cash outflows for the 2020 financial year of $4.73 million. The increase in cash for
the period was a result of a successful $5.8 million capital raise, which was strongly supported by
Institutions, as well as new and existing sophisticated and professional investors. Additionally,
Dimerix entered into a non-dilutive funding agreement with Radium Capital, providing $1.02
million in prepayment of the Company’s R&D tax incentive claim.
Operating cash outflows for the period comprised predominately of R&D expenditure for Phase
2 studies, including manufacturing and clinical costs. Whilst increasing R&D spend significantly
versus previous year, overheads were reduced and the Company finished the year under budget.
Cost management remains a key priority for the business, with the cost base being carefully
managed to ensure delivery of a sustainable business beyond the current milestones.
In accordance with Listing Rule 4.7C, payments made to related parties and their associates
included in item 6.1 of the Appendix 4C incorporates directors’ fees, salaries and superannuation.
Dimerix has multiple assets in commercially attractive and growing markets that have a high
unmet need, and with no current marketed competition, and with a potential fast pathway to
market. Dimerix has two Phase 2 clinical studies underway: DMX-200 for FSGS (top line data
expected before the end of July 2020); and DMX-200 for Diabetic Kidney Disease (last patient
scheduled to receive last dose in July 2020), DMX-700 for chronic obstructive pulmonary disease
(COPD), and DMX-200 in Acute Respiratory Distress Syndrome (ARDS) in patients with COVID-19
- Forums
- ASX - By Stock
- Ann: Quarterly Appendix 4C and Activities Report
DIMERIX QUARTERLY ACTIVITIES REPORTQuarter highlights• Last...
-
- There are more pages in this discussion • 217 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
43.5¢ |
Change
0.045(11.5%) |
Mkt cap ! $239.5M |
Open | High | Low | Value | Volume |
40.5¢ | 44.0¢ | 40.0¢ | $2.225M | 5.387M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 11627 | 43.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
43.5¢ | 126213 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 11627 | 0.430 |
1 | 39270 | 0.420 |
6 | 232044 | 0.415 |
7 | 227559 | 0.410 |
4 | 209270 | 0.405 |
Price($) | Vol. | No. |
---|---|---|
0.435 | 126213 | 4 |
0.440 | 202599 | 6 |
0.445 | 153522 | 6 |
0.450 | 178758 | 11 |
0.455 | 67471 | 2 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |